Genomics

Genomics is the science of analysing the genetic information contained in the DNA. Today, it is possible to link genetic variations with some specific traits. This means that based on your DNA, Therawin can calculate your risks for certain diseases (cancer, high blood pressure, cardiovascular diseases, metabolic diseases…), but also recommend the best diet or exercise routine for you to keep healthy and fit.

​Cancer genomics

Our technology can assess the variations in the genome occurring during cancer development. This is a critical information for physicians to provide a customised treatment to their cancer patients. Such personalised treatments generally show better therapeutic efficacy and fewer side effects.

Microbiomics

Our body is composed of trillions of our cells, but also trillions of micro-organisms living in symbiosis, especially in our guts and on our skin. This microbiota is closely connected with the human body systems and take an important part in our health. Interestingly, this microbiota is also related to our environment, our diet, our lifestyle. Analysing the microbiota, Therawin will unlock information about your environment, modifying your diet and lifestyle can modify your microbiota and have positive impact on your health. Your microbiota composition can also be used as a marker of your health in parallel to your genes. Your microbiota genes analysis also makes possible better prevention and treatment effects on diseases.

Therawin will soon offer personalised pro/pre-biotics supplements based on your gut microbiota analysis.

Transcriptomics

Through its partner in Korea, Therawin can provide Spatial Transcriptomics service that analyzes the characteristics of single cell. This technique allows to accurately assess the characteristics of cell that compose tumour tissues, it is utilised in the segmentation of targeted treatment and enhancement of efficiency in immune treatment with considerations for the micro-environment of the tumour.

Diagnostics

Beside the lateral flow tests, also known as lateral flow immunochromatographic assays or rapid tests, Therawin is working on a novel diagnostics platform unlocking the potential of nucleic acids for diagnostics.

The new platform will have the advantages of the PCR in terms of sensitivity and specificity, but without the need of heavy equipment and highly skilled staff to conduct the assay.

​